![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
NS3/4A BASELINE POLYMORPHISMS AND TREATMENT-EMERGENT VARIANTS IN HCV GENOTYPE-1-INFECTED, TREATMENT-NAIVE PATIENTS FROM THE PHASE III STARTVerso 1 AND 2 CLINICAL STUDIES OF FALDAPREVIR PLUS PEGYLATED INTERFERON α-2A AND RIBAVIRIN
|
|
|
Reported by Jules Levin
HEP DART 2013: December 8-12, Hawaii, USA.
AASLD: Boehringer Ingelheim - (11/18/13)
C Sarrazin1, KL Berger2, P Ferenci3, DM Jensen4, R Buynak5, J-F Dufour6, J-H Kao7, P Mantry8, LE Morano9, C Moreno10, SW Paik11, E Tam12, M Omata13, E Zehnter14, MS Sulkowski15, J Scherer2, JO Stern2, A-M Quinson2, and G Kukolj16
1J. W. Goethe University Hospital, Frankfurt, Germany; 2Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA; 3Medical University of Vienna, Vienna, Austria; 4University of Chicago Medicine, Chicago, IL, USA; 5Northwest Indiana Center for Clinical Research, Valparaiso, IN, USA; 6University Clinic for Visceral Surgery and Medicine, Bern, Switzerland; 7National Taiwan University Hospital, Taipei, Taiwan; 8The Liver Institute at Methodist Dallas Medical Center, Dallas, TX, USA; 9Hospital Meixoeiro, Vigo, Spain; 10Hôpital Universitaire Erasme, Université Libre de Bruxelles, Brussels, Belgium; 11Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea; 12LAIR Centre, Vancouver, BC, Canada; 13Yamanishi Central and Kita Hospitals, Yamanishi, Japan; 14Schwerpunktpraxis Hepatologie, Dortmund, Germany; 15John Hopkins University School of Medicine, Baltimore, MD, USA; 16Boehringer Ingelheim (Canada) Ltd, Burlington, ON, Canada
![AASLD1.gif](../images/121613/121613-7/AASLD1.gif)
![AASLD2.gif](../images/121613/121613-7/AASLD2.gif)
![AASLD3.gif](../images/121613/121613-7/AASLD3.gif)
![AASLD4.gif](../images/121613/121613-7/AASLD4.gif)
![AASLD5.gif](../images/121613/121613-7/AASLD5.gif)
![AASLD6.gif](../images/121613/121613-7/AASLD6.gif)
![AASLD7.gif](../images/121613/121613-7/AASLD7.gif)
![AASLD8.gif](../images/121613/121613-7/AASLD8.gif)
![AASLD9.gif](../images/121613/121613-7/AASLD9.gif)
![AASLD10.gif](../images/121613/121613-7/AASLD10.gif)
![AASLD11.gif](../images/121613/121613-7/AASLD11.gif)
![AASLD12.gif](../images/121613/121613-7/AASLD12.gif)
![AASLD13.gif](../images/121613/121613-7/AASLD13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|